{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:19:43Z","timestamp":1785395983475,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.cyto.2012.07.029","type":"journal-article","created":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T19:00:31Z","timestamp":1344970831000},"page":"522-527","source":"Crossref","is-referenced-by-count":22,"title":["Thalidomide attenuates multiple low-dose streptozotocin-induced diabetes in mice by inhibition of proinflammatory cytokines"],"prefix":"10.1016","volume":"60","author":[{"given":"K.","family":"Amirshahrokhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ghazi-Khansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2012.07.029_b0005","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.coi.2011.10.001","article-title":"Diabetogenic T lymphocytes in human type 1 diabetes","volume":"23","author":"Roep","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cyto.2012.07.029_b0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.2337\/db09-1562","article-title":"NOX2 deficiency protects against streptozotocin-induced beta-cell destruction and development of diabetes in mice","volume":"59","author":"Xiang","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2012.07.029_b0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diabres.2008.11.029","article-title":"NO-mediated cytotoxicity contributes to multiple low-dose streptozotocin-induced diabetes but not to NOD diabetes","volume":"83","author":"Yasuda","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cyto.2012.07.029_b0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0006-2952(97)00492-9","article-title":"Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus","volume":"55","author":"Rabinovitch","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cyto.2012.07.029_b0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.180605","article-title":"Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus","volume":"193","author":"Like","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.cyto.2012.07.029_b0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.taap.2008.06.020","article-title":"Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice","volume":"232","author":"Amirshahrokhi","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cyto.2012.07.029_b0035","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.cyto.2012.07.029_b0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1592\/phco.23.4.481.32115","article-title":"Thalidomide for erythema nodosum leprosum and other applications","volume":"23","author":"Okafor","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cyto.2012.07.029_b0045","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1208\/aapsj070103","article-title":"Properties of thalidomide and its analogues: implications for anticancer therapy","volume":"7","author":"Teo","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.cyto.2012.07.029_b0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ardp.200700217","article-title":"Thalidomide as a multi-template for development of biologically active compounds","volume":"341","author":"Hashimoto","year":"2008","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.cyto.2012.07.029_b0055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.det.2010.03.003","article-title":"Innovative uses of thalidomide","volume":"28","author":"Chen","year":"2010","journal-title":"Dermatol Clin"},{"issue":"140","key":"10.1016\/j.cyto.2012.07.029_b0060","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory agents: present and future","volume":"19","author":"Dinarello","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2012.07.029_b0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.taap.2011.03.017","article-title":"He effect of methylsulfonylmethane on the experimental colitis in the rat","volume":"253","author":"Amirshahrokhi","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cyto.2012.07.029_b0070","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.2337\/db07-1691","article-title":"Primer: immunity and autoimmunity","volume":"57","author":"Pietropaolo","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2012.07.029_b0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/clin.1994.1068","article-title":"Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse","volume":"71","author":"Pennline","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.cyto.2012.07.029_b0080","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1007\/s00018-005-5259-0","article-title":"Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells","volume":"62","author":"Miljkovic","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cyto.2012.07.029_b0085","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.4049\/jimmunol.1000788","article-title":"IL-17 immunity in human type 1 diabetes","volume":"185","author":"Honkanen","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2012.07.029_b0090","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2012.07.029_b0095","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1006\/jaut.2001.0506","article-title":"A transcriptional inhibitor of TNF-alpha prevents diabetes induced by multiple low-dose streptozotocin injections in mice","volume":"16","author":"Holstad","year":"2001","journal-title":"J Autoimmun"},{"key":"10.1016\/j.cyto.2012.07.029_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0162-3109(98)00010-1","article-title":"Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells","volume":"40","author":"Rowland","year":"1998","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.cyto.2012.07.029_b0105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","article-title":"The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures","volume":"99","author":"McHugh","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cyto.2012.07.029_b0110","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.bcp.2004.06.018","article-title":"Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat","volume":"68","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cyto.2012.07.029_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cellimm.2004.09.003","article-title":"Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner","volume":"230","author":"Payvandi","year":"2004","journal-title":"Cell Immunol"},{"key":"10.1016\/j.cyto.2012.07.029_b0120","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2012.07.029_b0125","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.cyto.2012.07.029_b0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn\u2019s disease","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.cyto.2012.07.029_b0135","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4049\/jimmunol.179.1.708","article-title":"Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice","volume":"179","author":"Tabata","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2012.07.029_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/shk.0b013e318067df68","article-title":"Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis","volume":"29","author":"Malleo","year":"2008","journal-title":"Shock"},{"key":"10.1016\/j.cyto.2012.07.029_b0145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1248\/cpb.52.498","article-title":"Thalidomide as a nitric oxide synthase inhibitor and its structural development","volume":"52","author":"Shimazawa","year":"2004","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.cyto.2012.07.029_b0150","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/jpet.300.3.876","article-title":"Nicotine reduces the incidence of type I diabetes in mice","volume":"300","author":"Mabley","year":"2002","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466612006114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466612006114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T09:35:11Z","timestamp":1687685711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466612006114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1043466612006114"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2012.07.029","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}